Yatiri Bio
Yatiri Bio is revolutionizing drug discovery by integrating proteomics, deep learning, and patient data to improve clinical development and patient outcomes. The company focuses on developing novel tools for analyzing proteins as functional drivers of disease, facilitating the discovery of therapeutic signatures, and predicting patient outcomes to match individualized therapeutics, aiming to transform current medical practices.
Industries
Nr. of Employees
small (1-50)
Yatiri Bio
San Diego, California, United States, North America
Products
ProteoModelsTM
A portfolio of cellular models backed by clinical proteome data, used for patient selection, combinational therapies, drug repurposing, identifying resistance mechanisms, and drug discovery with biomarkers.
ProteoBrowserTM
An interactive platform integrating proteomics data, computational biology, and machine learning for drug discovery, providing access to proprietary and public proteomic data.
PTM Enrichment and Analysis
A service offering tailored post-translational modification enrichment and analysis to discover signaling pathways, including a pipeline optimized for phosphoproteomics.
Efficacy Models
A collection of tailored models for identifying therapeutic indications, selecting ideal patients for clinical trials, and exploring combination therapies with deep pathway analysis and biomarker identification.
ProteoModelsTM
A portfolio of cellular models backed by clinical proteome data, used for patient selection, combinational therapies, drug repurposing, identifying resistance mechanisms, and drug discovery with biomarkers.
ProteoBrowserTM
An interactive platform integrating proteomics data, computational biology, and machine learning for drug discovery, providing access to proprietary and public proteomic data.
PTM Enrichment and Analysis
A service offering tailored post-translational modification enrichment and analysis to discover signaling pathways, including a pipeline optimized for phosphoproteomics.
Efficacy Models
A collection of tailored models for identifying therapeutic indications, selecting ideal patients for clinical trials, and exploring combination therapies with deep pathway analysis and biomarker identification.
Services
Unbiased quantitative proteomic analysis via high-resolution mass spectrometry for cell lines, organoids, tissues, and clinical samples with optimized processing protocols.
Tailored enrichment and analytical workflows to detect and quantify post-translational modifications and signaling events relevant to disease biology.
Integrated bioinformatics analysis using a proteomic database to identify biomarker signatures, mechanisms of resistance, and markers for patient selection.
Development and application of deep learning models that map proteomic readouts to predicted patient outcomes to inform clinical development and trial design.
Web-based portal for interrogation of experimental proteomic data in the context of internal and public databases to facilitate data exploration and decision making.
Unbiased quantitative proteomic analysis via high-resolution mass spectrometry for cell lines, organoids, tissues, and clinical samples with optimized processing protocols.
Tailored enrichment and analytical workflows to detect and quantify post-translational modifications and signaling events relevant to disease biology.
Integrated bioinformatics analysis using a proteomic database to identify biomarker signatures, mechanisms of resistance, and markers for patient selection.
Development and application of deep learning models that map proteomic readouts to predicted patient outcomes to inform clinical development and trial design.
Web-based portal for interrogation of experimental proteomic data in the context of internal and public databases to facilitate data exploration and decision making.
Expertise Areas
- Mass spectrometry–based proteomics
- Phosphoproteomics and PTM analysis
- Proteomic biomarker discovery
- Bioinformatics for proteomics
Key Technologies
- High-resolution mass spectrometry
- Phosphoproteomics
- Post-translational modification enrichment
- Proteomic databases
News & Updates
Mass-spectrometry-based proteomic profiling of human cancers to identify molecular subtypes and pathway features, classifying 532 cancers across six tissue types.
Deep proteomic profiling revealing mechanistic differences among medulloblastomas, defining higher risk subsets and potential therapeutic targets.
Unbiased analysis of breast tumor proteomes, quantifying 9995 proteins across tumors, recapitulating breast cancer molecular characterization.
Identification of colon cancer-associated proteins, neoantigens, and potential therapeutic targets, including Rb phosphorylation and glycolysis inhibition.
Mass-spectrometry-based proteomic profiling of human cancers to identify molecular subtypes and pathway features, classifying 532 cancers across six tissue types.
Deep proteomic profiling revealing mechanistic differences among medulloblastomas, defining higher risk subsets and potential therapeutic targets.
Unbiased analysis of breast tumor proteomes, quantifying 9995 proteins across tumors, recapitulating breast cancer molecular characterization.
Identification of colon cancer-associated proteins, neoantigens, and potential therapeutic targets, including Rb phosphorylation and glycolysis inhibition.